Monday, August 13, 2012

For good or...

...for evil? The debate continues

The world looked at biotechnology with immense hope and expectations four decades ago. People look at the advancements even today with the same hope; albeit tempered by some speculations. Biotechnology has long carried hopes of revolutionising medical science and agriculture on its shoulders.

Indubitably, the biotech industry is highly progressive. It is one of the most research-intensive industries. For instance, while in 2006, publicly traded biotech companies in the US spent around $27.1 billion on R&D (and created 180,000 employment opportunities; all life-sciences activities generated 1.3 million jobs directly in 2006 and an additional 7.5 million jobs indirectly), in 2010, the industry is expected to generate $100 billion in revenues annually. Over 5,000 companies are operating worldwide in the field of biotechnological product development and innovations.